Intelligence in Service of Hope

Interpretable AI that Personalizes Cancer Care

We transform multimodal patient data into real-time, transparent insights that improve oncology outcomes and accelerate drug development.

Request a Pilot Learn More

Why It Matters

43,170

U.S. women died of breast cancer in 2023

50%

Stage I–III patients (≈280,000 in 2024) relapse within 20 years

<5%

Enroll in oncology trials

10‑17 yrs

Average time to bring therapy to market

The i⁴ Platform

Intelligent, Individualized, Interpretable, Integrated—engineered to deliver proactive, patient-specific interventions at the point of care through secure API integration with real-time inference capabilities.

Intelligent

State-of-the-art AI trained on >200k patient records

Individualized

Personalized survival curves & risk scores

Interpretable

SHAP-based explainability for clinical trust

Integrated

Seamless EHR, genomics, and imaging integration

Clinical Solutions

Survival Optimizer

Personalized survival curves & "what-if" therapy scenarios

Recurrence Sentinel

Early-warning scores for Stage I–III survivors

Trial Match Pro

Dynamic eligibility & outcome forecasting for trials

Precision Repurposer

Identify new indications for FDA-approved drugs

Explainability Hub

Transparent dashboards for clinicians & regulators

Clinical Evidence & Commercial Traction

>90% Predictive Accuracy

Validated on retrospective cohorts >200k patients with peer-reviewed publications

Regulatory-Grade Explainability

FDA/EMA review-ready with comprehensive model interpretability

3 Health-System Pilots Underway

Active deployments with leading cancer centers validating clinical utility

HIPAA + SOC 2 Compliant

Enterprise-grade security with SOC 2 Type II audit in progress

Patent-Pending Fusion IP

Defensible multimodal algorithm for oncology decision support

Provisional Patent Filed

Intellectual property protection for core AI methodologies and clinical applications

Leadership Team

Nabil Adam, Ph.D.

Co-founder & CEO — Top-2% AI scholar, Serial entrepreneur (first startup exit 2008)

Tarek Adam, MD, M.Sc.

Co-founder & Chief Medical Officer — DHMC/NY-Presbyterian/Weill Cornell psychiatrist-oncologist, Expert in oncology-psychiatry comorbidity

Robert Wieder, MD, Ph.D.

Chief Scientific Officer — NIH & MSK-trained oncologist, Led breakthroughs in gene therapy, cancer signaling & breast-cancer dormancy

Mojtaba Hasannezhad, PhD

Chief Technology Officer — Enterprise AI & cloud architect